| Cytogenetics Morphological | t(5;14), like other cryptic chromosomal aberrations, was discovered relatively recently and most subsequent studies have focused on molecular and clinical aspects of this entity to the exclusion of cytogenetics. This gap is aggravated by the uniquely large breakpoint cluster region (bcr) of the 14q32 partner gene, BCL11B (alias CTIP2, RIT1). Hence, detailed documentation of this interesting rearrangement is largely based on data obtained using t(5;14) T-ALL cell lines which hitherto all carry submicroscopic insertions, both ins(5;14) and ins(14;5), instead of conventional reciprocal translocations. If verified in patient material, detailed analysis of such configurations may reveal neighboring genes or regulators inimical to the oncogenic activity of t(5;14), and therefore excluded by the more selective insertional rearrangements. |
| |  |
| |
| |
G-banding of t(5;14)(q35;q32.2) in a pediatric T-ALL leukemia cell line (CCRF-CEM) illustrating the cryptic nature of this rearrangement. Hence normal and rearranged homologs are indistinguishable by G-banding, as are standard and rare variant t(5;14) subtypes. In chromosome painting images only a minority of cells in even superior preparations show the t(5;14). |
| |
| Cytogenetics Molecular | The proximities of the 14q32.2, and of both standard and variant 5q35 breakpoints to their respective telomeres, impairs FISH detection using chromosome painting probes except in optimal preparations. The tendency of t(5;14) to involve microinsertions (in both directions), together with the sheer magnitude of the BCL11B bcr, impedes detection by specific BAC/PAC combinations. |
| |  |
| |
| |
Upper image depicts results of chromosome painting in an above average T-ALL cell (CCRF-CEM) with t(5;14) and concurrent ins(14;5). Note absence of visible signs betraying reciprocal exchange. Chromosome painting was performed using Cambio probes (Cambridge, UK) for chromosomes 5 (TexasRed), and 14 (Cy3). Middle image depicts standard t(5;14)(q35.1;q32.2) as represented by ins(5;14)(q35.1;q32.2q32.2) in cell line DND-41 which activates TLX3 transcription by juxtaposition with part of the noncoding region of BCL11B (clones shown below). Insert shows fiber-FISH confirming the regions juxtaposed. Lower image summarizes breakpoint data for t(5;14)(q35;q32) in T-ALL at three loci: TLX3 (standard translocation), NKX2-5 (variant translocation), and BCL11B (both translocations). Patient and cell line breakpoints are shown red and blue, respectively, together with insertion data from cell line DND-41. The NKX2-5 patient breakpoint included for comparison is from a t(5;14)(q35.2;q11.2) patient where TRAD is the activating partner. Coordinates are given in Mbp. Note the circa 1 Mbp 14q32.2 bcr which effectively covers the 3'-BCL11B regulatory region, while TLX3 breakpoints cover a "modest" 90 Kbp. NKX2-5 cases are too rare to allow bcr delineation. |
| |
| Probes | The widespread involvement of cryptic rearrangements, notably microinsertions, plus the sheer length of the 14q32.2 breakpoint cluster complicates diagnostic probe design. Sensitive molecular cytogenetic diagnosis requires a BAC contig-battery covering bcr at both 5q35 and 14q32. Given the ectopic - all or none - nature of TLX3 expression in affected cells, screening t(5;14) is probably better performed by RT-PCR. |
| Variants | A microscopically synonymous variant, t(5;14)(q35.2;q32.2), whereby the closely related and neighboring NKX2-5 is juxtaposed to BCL11B, has proved frustratingly difficult to identify clinically despite occurring in two widely used T-ALL cell lines, CCRF-CEM and PEER. NKX2-5 is ectopically activated in t(5;14)(q35.2;q11.2) where it is juxtaposed with TRAD. The diagnostic caveats for the standard translocation also apply: detection of variant t(5;14) by RT-PCR is likely to pose fewer technical difficulties than cytogenetic detection by FISH. |
| A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. |
| Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M, Della Valle V, Monni R, Nguyen Khac F, Mercher T, Penard-Lacronique V, Pasturaud P, Gressin L, Heilig R, Daniel MT, Lessard M, Berger R. |
| Leukemia. 2001 Oct;15(10):1495-504. |
| PMID 11587205 |
| |
| The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. |
| Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL, Liu H, Price HP, Gesk S, Steinemann D, Schlegelberger B, Oscier DG, Siebert R, Tucker PW, Dyer MJ. |
| Blood. 2001 Dec 1;98(12):3413-20. |
| PMID 11719382 |
| |
| Activation of HOX11L2 by juxtaposition with 3'-BCL11B in an acute lymphoblastic leukemia cell line (HPB-ALL) with t(5;14)(q35;q32.2). |
| MacLeod RAF, Nagel S, Kaufmann M, Janssen JW, Drexler HG. |
| Genes Chromosomes Cancer. 2003 May;37(1):84-91. |
| PMID 12661009 |
| |
| The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). |
| Nagel S, Kaufmann M, Drexler HG, MacLeod RA. |
| Cancer Res. 2003 Sep 1;63(17):5329-34. |
| PMID 14500364 |
| |
| Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. |
| Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A, Malet M, Boutard P, Benoit Y, Mauvieux L, Lutz P, Méchinaud F, Grardel N, Mazingue F, Dupont M, Margueritte G, Pages MP, Bertrand Y, Plouvier E, Brunie G, Bastard C, Plantaz D, Vande Velde I, Hagemeijer A, Speleman F, Lessard M, Otten J, Vilmer E, Dastugue N; EORTC-CLG. |
| Blood. 2004 Jan 15;103(2):442-50. Epub 2003 Sep 22. |
| PMID 14504110 |
| |
| BCL11B rearrangements probably target T-cell neoplasia rather than acute myelocytic leukemia. |
| MacLeod RA, Nagel S, Drexler HG. |
| Cancer Genet Cytogenet. 2004 Aug;153(1):88-9. |
| PMID 15325104 |
| |
| Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia. |
| Su XY, Busson M, Della Valle V, Ballerini P, Dastugue N, Talmant P, Ferrando AA, Baudry-Bluteau D, Romana S, Berger R, Bernard OA. |
| Genes Chromosomes Cancer. 2004 Nov;41(3):243-9. |
| PMID 15334547 |
| |
| Significance of HOX11L2/TLX3 expression in children with T-cell acute lymphoblastic leukemia treated on Children's Cancer Group protocols. |
| Gottardo NG, Jacoby PA, Sather HN, Reaman GH, Baker DL, Kees UR. |
| Leukemia. 2005 Sep;19(9):1705-8. |
| PMID 15990867 |
| |
| Inhibition of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-ALL after Blocking Remote 3'-BCL11B Enhancer Sequences with Matching DNA Oligos Reveals Coregulation by PU.1 and HMGA1. |
| Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RAF. |
| Blood , 2006; 108: 2212. |
| |
| Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3. |
| Su X, Drabkin H, Clappier E, Morgado E, Busson M, Romana S, Soulier J, Berger R, Bernard OA, Lavau C. |
| Genes Chromosomes Cancer. 2006 Sep;45(9):846-55. |
| PMID 16804919 |
| |
| HOX11L2/TLX3 is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32). |
| Su XY, Della-Valle V, Andre-Schmutz I, Lemercier C, Radford-Weiss I, Ballerini P, Lessard M, Lafage-Pochitaloff M, Mugneret F, Berger R, Romana SP, Bernard OA, Penard-Lacronique V. |
| Blood. 2006 Dec 15;108(13):4198-201. Epub 2006 Aug 22. |
| PMID 16926283 |
| |
| The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. |
| van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den Boer ML, Horstmann M, Kamps WA, Veerman AJ, van Wering ER, van Noesel MM, Pieters R. |
| Haematologica. 2006 Sep;91(9):1212-21. |
| PMID 16956820 |
| |
| Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. |
| Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RA. |
| Cancer Res. 2007 Feb 15;67(4):1461-71. |
| PMID 17308084 |
| |
| MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. |
| Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, MacLeod RA. |
| Leukemia. 2008 Mar;22(3):600-7. Epub 2007 Dec 13. |
| PMID 18079734 |
| |
| Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. |
| van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R. |
| Leukemia. 2008 Jan;22(1):124-31. Epub 2007 Oct 11. |
| PMID 17928886 |
| |
| Cooperative genetic defects in TLX3 rearranged pediatric T-ALL. |
| Van Vlierberghe P, Homminga I, Zuurbier L, Gladdines-Buijs J, van Wering ER, Horstmann M, Beverloo HB, Pieters R, Meijerink JP. |
| Leukemia. 2008 Apr;22(4):762-70. Epub 2008 Jan 10. |
| PMID 18185524 |
| |